참고문헌
- Akhsan A, Aryandono T (2010). Prognostic factors of locally advanced breast cancer patients receiving neoadjuvant and adjuvant chemotherapy. Asian Pac J Cancer Prev. 11, 759-61.
- Ambrosini G, Balli M, Garusi G, et al (1988). Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin. J Clin Oncol, 6, 976-82.
- Anaya-Ruiz M, Vallejo-Ruiz V, Flores-Mendoza L, Perez-Santos M (2014). Female breast cancer incidence and mortality in Mexico, 2000-2010. Asian Pac J Cancer Prev, 15, 1477-9. https://doi.org/10.7314/APJCP.2014.15.3.1477
- Anders CK, Hsu DS, Broadwater G, et al (2008). Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol, 26, 3324-30. https://doi.org/10.1200/JCO.2007.14.2471
- Balakrishnan N, Rao CR (2002). Race, socioeconomic status, and breast cancer treatment and survival. Elsevier Science B.V.
- Banegas MP, Li CI (2012). Breast cancer characteristics and outcomes among Hispanic Black and Hispanic White women. Breast Cancer Res Treat, 134, 1297-304. https://doi.org/10.1007/s10549-012-2142-1
-
Basaran G, Devrim C, Caglar HB, et al (2011). Clinical outcome of breast cancer patients with N3a (
${\geq}$ 10 positive lymph nodes) disease: has it changed over years? Med Oncol, 28, 726-32. https://doi.org/10.1007/s12032-010-9516-1 - Blue L, Fenelon A. (2011). Explaining low mortality among US immigrants relative to native-born Americans: the role of smoking. Int J Epidemiol, 40, 786-93. https://doi.org/10.1093/ije/dyr011
- Buzdar AU, Kau SW, Hortobagyi GN, et al (1992). Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer, 69, 448-52. https://doi.org/10.1002/1097-0142(19920115)69:2<448::AID-CNCR2820690229>3.0.CO;2-K
- Buzdar A, Jonat W, Howell A, et al (1996). Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol, 14, 2000-11.
- Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492. https://doi.org/10.1001/jama.295.21.2492
- Colleoni M, Rotmensz N, Peruzzotti G, et al (2005). Size of breast cancer metastases in axillary lymph nodes: clinical relevance ofminimal lymph node involvement. J Clin Oncol, 23, 1379-89 https://doi.org/10.1200/JCO.2005.07.094
- Danko ME, Bennett KM, Zhai J, Marks JR, Olson JA Jr (2010) Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with longterm follow-up. J Am Coll Surg, 210, 797-805. https://doi.org/10.1016/j.jamcollsurg.2010.02.045
- Duman BB, Afsar CU, GUnaldi M, et al (2012). Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients. Asian Pac J Cancer Prev, 13, 4119-23. https://doi.org/10.7314/APJCP.2012.13.8.4119
- Edge S, Byrd D, Compton C, et al (2010). American Joint Committee on Cancer. AJCC Cancer Staging Manual, 7th ed.
- Fan C, Oh DS, Wessels L, et al (2006). Concordance among gene-expression-based predictors for breast cancer. N Engl J Med, 355, 560. https://doi.org/10.1056/NEJMoa052933
- Giordano SH (2003). Update on locally advanced breast cancer. Oncologist, 8, 521-30. https://doi.org/10.1634/theoncologist.8-6-521
- Han SJ, Guo QQ, Wang T, et al (2013). Prognostic significance of interactions between ER alpha and ER beta and lymph node status in breast cancer cases. Asian Pac J Cancer Prev, 14, 6081-4. https://doi.org/10.7314/APJCP.2013.14.10.6081
- Howlader N, Noone AM, Krapcho M, et al (2012).SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, SEER data submission, posted to the SEER web site, 2012.
- Hu Z, Fan C, Oh DS, et al (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics, 7, 96. https://doi.org/10.1186/1471-2164-7-96
- Keramatinia A, Mousavi-Jarrahi SH, Hiteh M, Mosavi-Jarrahi A (2014). Trends in incidence of breast cancer among women under 40 in Asia. Asian Pac J Cancer Prev, 15, 1387-90. https://doi.org/10.7314/APJCP.2014.15.3.1387
-
Koca E, Kuzan TY, Dizdar O, et al (2013). Outcomes of locally advanced breast cancer patients with
${\geq}$ 10 positive axillary lymph nodes. Med Oncol, 30, 615. https://doi.org/10.1007/s12032-013-0615-7 - Lee JS, Kim SI, Choi SY, et al (2011). Factors influencing the outcome of breast cancer patients with 10 or more metastasized axillary lymph nodes. Int J Clin Oncol, 16, 473-81. https://doi.org/10.1007/s10147-011-0207-5
- Livaudais JC, Hershman DL, Habel L, et al (2012). Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat, 131, 607-17. https://doi.org/10.1007/s10549-011-1762-1
- Livi L, Meattini I, Saieva C, et al (2012). Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. Cancer, 118, 3236-43. https://doi.org/10.1002/cncr.26647
- Mieog JS, van der Hage JA, van de Velde CJ. (2007). Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev.
- Montero AJ, Rouzier R, Lluch A, et al (2005). The natural history of breast carcinoma in patients with > or=10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study. Cancer, 104, 229-35. https://doi.org/10.1002/cncr.21182
- Nabholtz JM, Mackey JR, Smylie M, et al (2001). Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-linechemotherapy for metastatic breast cancer. J Clin Oncol, 19, 314-21
- Palmer JR, Wise LA, Horton NJ, Adams-Campbell LL, Rosenberg L (2003). Dual effect of parity on breast cancer risk in African-American women. J Natl Cancer Inst, 95, 478. https://doi.org/10.1093/jnci/95.6.478
- Parker JS, Mullins M, Cheang MC, et al (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol, 27, 1160. https://doi.org/10.1200/JCO.2008.18.1370
-
Prajoko YW(1), Aryandono T (2014). Expression of nuclear factor kappa B (NF-
$\kappa$ B) as a predictor of poor pathologic response to chemotherapy in patients with locally advanced breast cancer. Asian Pac J Cancer Prev, 15, 595-8. https://doi.org/10.7314/APJCP.2014.15.2.595 - Ragaz J, Jackson SM, Le N, et al (1997). Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med, 337, 956-62. https://doi.org/10.1056/NEJM199710023371402
- Rezaianzadeh A, Talei A, Rajaeefard A et al (2012). Vascular invasion as an independent prognostic factor in lymph node negative invasive breast cancer. Asian Pac J Cancer Prev, 13, 5767-72 https://doi.org/10.7314/APJCP.2012.13.11.5767
- Ries LAG, Eisner MP and Kosary CL. (2001). SEER Cancer Statistics Review, 1973-1998, National Cancer Institute.
- Robertson FM, Bondy M, Yang W, et al (2010). Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin, 60, 351-75 https://doi.org/10.3322/caac.20082
- Schmoor C, Sauerbrei W, Bastert G, Bojar H, Schumacher M (2001). Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer, 37, 1123-31. https://doi.org/10.1016/S0959-8049(01)00090-9
- Suciu, GP, Lemeshow S, Moeschberger M (2004). Statistical Test of Equality of Survival Curves: Reconsidering the Options, Handbook of Statistics, Vol.23, Chapter 13. Eds.
- Turra CM, Elo IT (2008). The Impact of Salmon Bias on the Hispanic Mortality Advantage: New Evidence from Social Security Data. Popul Res Policy Rev, 27, 515-30. https://doi.org/10.1007/s11113-008-9087-4
- VanderWalde A, Ye W, Frankel P, et al (2012). Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer. Biol Blood Marrow Transplant, 18, 1273-80. https://doi.org/10.1016/j.bbmt.2012.01.021
- Vinh-Hung V, Verschraegen C, Promish DI, et al (2004) Ratios of involved nodes in early breast cancer. Breast Cancer Res, 6, 680-8. https://doi.org/10.1186/bcr934
- Voduc KD, Cheang MC, Tyldesley S, et al (2010). Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol, 28, 1684. https://doi.org/10.1200/JCO.2009.24.9284
- Woodward WA, Strom EA, Tucker SL, et al (2003) Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol, 21, 3244-8 https://doi.org/10.1200/JCO.2003.03.052
- Woodward WA, Huang EH, McNeese MD, et al (2006).African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy. Cancer, 107, 2662-8. https://doi.org/10.1002/cncr.22281
- Woodward WA, Vinh-Hung V, Ueno NT, et al (2006) Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol, 24, 2910-6. https://doi.org/10.1200/JCO.2005.03.1526
- Zeichner SB, Zeichner SB, Ruiz AL, Markward NJ, Rodriguez E (2014). Improved long-term survival with contralateral prophylactic mastectomy among young women. Asian Pac J Cancer Prev, 15, 1155-62. https://doi.org/10.7314/APJCP.2014.15.3.1155
피인용 문헌
- Fitting Cure Rate Model to Breast Cancer Data of Cancer Research Center vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7923
- Radiotherapy of brain metastases from breast cancer: Treatment results and prognostic factors vol.11, pp.5, 2016, https://doi.org/10.3892/ol.2016.4349